|Day Low/High||1.70 / 1.85|
|52 Wk Low/High||0.90 / 3.00|
VERU-944 to Advance to Phase 2 Clinical Trial; 505(b)(2) Drug Candidate Addresses $600 Million Market, Potentially the First Drug for This Indication
Veru Healthcare (NASDAQ: FHCO) today announced positive results from a Phase 4 clinical study of its proprietary product PREBOOST (topical 4% benzocaine wipes) for the management of premature ejaculation (PE).
Abstract Selected for Podium Presentation and Inclusion in 2017 AUA Press Conference
Female Health Co./Veru Healthcare's stock is down, but the company says it's not out.
Stage 1 of Clinical Trial Designed to Select Formulation; NDA Filing Under the 505(b)(2) Regulatory Pathway Late 2017 / Early 2018 And Approval Expected by Mid to Late 2018
-MSS-722 to Advance into Phase 2 Study; Trial Expected to Commence in 2017-
Company Plans to Launch Product in US Before Year End
Company Promotes Denise van Dijk to President of Global Public Health Sector Division
Company to Discuss Clinical Trial Design and Primary Clinical Endpoints for Phase 2 Study of Its Drug Candidate for Male Infertility
Remaining Proposals Close to Receiving the Required Super Majority Vote
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.